• Study: Rituxan Reduces Disease Activity in EGPA, But Relapses Stay High
  • Eurordis Unveils Integrated-care Initiative for Rare Disease Patients
  • Rituxan Is Cost-effective for ANCA-associated Vasculitis, Study Says
  • ‘Rare Barometer’ Program Helps Eurordis Shape EU Rare Disease Policy
  • Proteins Linked to Neutrophil Clearance Altered in GPA Patients, Study Finds
  • FDA Grants Priority Review to Rituxan Plus Glucocorticoids for Children with GPA and MPA
  • FDA Approves Autoinjector and Pre-filled Syringe for Self-Administration of Nucala
  • High Levels of MPO-ANCA Antibodies Linked to Poor Kidney Function in Long-term, Study Says
  • AAV Patients More Likely to Develop Thyroid Disease, Korean Study Finds
  • Plasma Exchange Effective for AAV Patients with Severe Renal Damage, Study Reports
  • BVAS and FFS Both Useful Tools for Predicting AAV Prognosis and Choosing Therapy, Study Says
  • Rituxan-Soliris Combo May Replace Glucocorticoids in Treatment of Severe AAV, Case Report Suggests